FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508460892> ?p ?o ?g. }

• W2508460892 endingPage "2258" @default.
• W2508460892 startingPage "2247" @default.
• W2508460892 abstract "Two randomized, double-blind trials have compared tamoxifen 20 mg daily and the selective, nonsteroidal aromatase inhibitor anastrozole 1 mg daily as first-line therapy for advanced breast carcinoma (ABC) in postmenopausal women. The trials were prospectively designed to allow for combined data analyses.The combined study population included 1021 postmenopausal women (median age, 67 years [range, 30-92]) with ABC whose tumors were either estrogen and/or progesterone receptor positive or of unknown receptor status. Primary endpoints were time to progression (TTP), objective response, and tolerability.At a median duration of follow-up of 18.2 months, anastrozole was at least equivalent to tamoxifen in terms of median TTP (8.5 and 7.0 months, respectively; estimated hazard ratio [tamoxifen relative to anastrozole], 1.13 [lower 95% confidence level, 1.00]). In a retrospective subgroup analysis, anastrozole was superior to tamoxifen with respect to TTP (median values of 10.7 and 6.4 months for anastrozole and tamoxifen, respectively, two-sided P = 0.022) in patients with estrogen and/or progesterone receptor positive tumors (60% of combined trial population). In terms of objective response, 29.0% of anastrozole and 27.1% of tamoxifen patients achieved either a complete response (CR) or a partial response (PR). Clinical benefit (CR + PR + stabilization of > or = 24 weeks) rates were 57.1% and 52.0% for anastrozole and tamoxifen, respectively. Both anastrozole and tamoxifen were well tolerated. Anastrozole led to significantly fewer venous thromboembolic (P = 0.043; not adjusted for multiple comparisons) events, and vaginal bleeding was reported in fewer patients treated with anastrozole than with tamoxifen.In postmenopausal women with hormonally sensitive ABC, anastrozole should be considered as the new standard first-line treatment." @default.
• W2508460892 created "2016-09-16" @default.
• W2508460892 creator A5003646311 @default.
• W2508460892 creator A5003654255 @default.
• W2508460892 creator A5018170018 @default.
• W2508460892 creator A5024118579 @default.
• W2508460892 creator A5027944082 @default.
• W2508460892 creator A5047212102 @default.
• W2508460892 creator A5071158497 @default.
• W2508460892 creator A5072927466 @default.
• W2508460892 creator A5073889721 @default.
• W2508460892 date "2001-01-01" @default.
• W2508460892 modified "2023-10-16" @default.
• W2508460892 title "Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma" @default.
• W2508460892 cites W1562190372 @default.
• W2508460892 cites W1810933484 @default.
• W2508460892 cites W1932574503 @default.
• W2508460892 cites W1994207027 @default.
• W2508460892 cites W2002905683 @default.
• W2508460892 cites W2024793633 @default.
• W2508460892 cites W2057459166 @default.
• W2508460892 cites W2058681718 @default.
• W2508460892 cites W2077614287 @default.
• W2508460892 cites W2132846837 @default.
• W2508460892 cites W2137960551 @default.
• W2508460892 cites W2141647078 @default.
• W2508460892 cites W2149855782 @default.
• W2508460892 cites W2169073956 @default.
• W2508460892 cites W2531714110 @default.
• W2508460892 cites W4230686738 @default.
• W2508460892 doi "https://doi.org/10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y" @default.
• W2508460892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11745278" @default.
• W2508460892 hasPublicationYear "2001" @default.
• W2508460892 type Work @default.
• W2508460892 sameAs 2508460892 @default.
• W2508460892 citedByCount "539" @default.
• W2508460892 countsByYear W25084608922012 @default.
• W2508460892 countsByYear W25084608922013 @default.
• W2508460892 countsByYear W25084608922014 @default.
• W2508460892 countsByYear W25084608922015 @default.
• W2508460892 countsByYear W25084608922016 @default.
• W2508460892 countsByYear W25084608922017 @default.
• W2508460892 countsByYear W25084608922018 @default.
• W2508460892 countsByYear W25084608922019 @default.
• W2508460892 countsByYear W25084608922020 @default.
• W2508460892 countsByYear W25084608922021 @default.
• W2508460892 countsByYear W25084608922022 @default.
• W2508460892 countsByYear W25084608922023 @default.
• W2508460892 crossrefType "journal-article" @default.
• W2508460892 hasAuthorship W2508460892A5003646311 @default.
• W2508460892 hasAuthorship W2508460892A5003654255 @default.
• W2508460892 hasAuthorship W2508460892A5018170018 @default.
• W2508460892 hasAuthorship W2508460892A5024118579 @default.
• W2508460892 hasAuthorship W2508460892A5027944082 @default.
• W2508460892 hasAuthorship W2508460892A5047212102 @default.
• W2508460892 hasAuthorship W2508460892A5071158497 @default.
• W2508460892 hasAuthorship W2508460892A5072927466 @default.
• W2508460892 hasAuthorship W2508460892A5073889721 @default.
• W2508460892 hasBestOaLocation W25084608921 @default.
• W2508460892 hasConcept C121608353 @default.
• W2508460892 hasConcept C126322002 @default.
• W2508460892 hasConcept C126894567 @default.
• W2508460892 hasConcept C143998085 @default.
• W2508460892 hasConcept C197934379 @default.
• W2508460892 hasConcept C207103383 @default.
• W2508460892 hasConcept C2776215463 @default.
• W2508460892 hasConcept C2777176818 @default.
• W2508460892 hasConcept C2778375690 @default.
• W2508460892 hasConcept C2778504769 @default.
• W2508460892 hasConcept C2908647359 @default.
• W2508460892 hasConcept C29456083 @default.
• W2508460892 hasConcept C44249647 @default.
• W2508460892 hasConcept C530470458 @default.
• W2508460892 hasConcept C71924100 @default.
• W2508460892 hasConcept C99454951 @default.
• W2508460892 hasConceptScore W2508460892C121608353 @default.
• W2508460892 hasConceptScore W2508460892C126322002 @default.
• W2508460892 hasConceptScore W2508460892C126894567 @default.
• W2508460892 hasConceptScore W2508460892C143998085 @default.
• W2508460892 hasConceptScore W2508460892C197934379 @default.
• W2508460892 hasConceptScore W2508460892C207103383 @default.
• W2508460892 hasConceptScore W2508460892C2776215463 @default.
• W2508460892 hasConceptScore W2508460892C2777176818 @default.
• W2508460892 hasConceptScore W2508460892C2778375690 @default.
• W2508460892 hasConceptScore W2508460892C2778504769 @default.
• W2508460892 hasConceptScore W2508460892C2908647359 @default.
• W2508460892 hasConceptScore W2508460892C29456083 @default.
• W2508460892 hasConceptScore W2508460892C44249647 @default.
• W2508460892 hasConceptScore W2508460892C530470458 @default.
• W2508460892 hasConceptScore W2508460892C71924100 @default.
• W2508460892 hasConceptScore W2508460892C99454951 @default.
• W2508460892 hasIssue "9" @default.
• W2508460892 hasLocation W25084608921 @default.
• W2508460892 hasLocation W25084608922 @default.
• W2508460892 hasOpenAccess W2508460892 @default.
• W2508460892 hasPrimaryLocation W25084608921 @default.
• W2508460892 hasRelatedWork W1532577738 @default.
• W2508460892 hasRelatedWork W2006377436 @default.

• next